Listen to expert faculty discuss the paradigm shift for cardiologists in understanding how to use SGLT2is and GLP-1RAs safely and effectively in their practice. This discussion focuses on when and how to safely commence these drugs, as well as when and how to engage other members of the care team.

Supplemental Slides 

Educational grant support provided by: Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

To visit the hub for the CV Risk in Diabetes: Emerging Science Grant, click here!

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Prevention, Lipid Metabolism

Keywords: Primary Prevention, Diabetes Mellitus, Dyslipidemias, Sodium-Glucose Transporter 2

< Back to Listings